Neuronetics (STIM) 10-Q7 Nov 232023 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2023	Nov. 02, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-38546
Entity Registrant Name	NEURONETICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-1051425
Entity Address, Address Line One	3222 Phoenixville Pike
Entity Address, City or Town	Malvern
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19355
City Area Code	610
Local Phone Number	640-4202
Title of 12(b) Security	Common Stock ($0.01 par value)
Trading Symbol	STIM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		28,933,132
Entity Central Index Key	0001227636
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Ex Transition Period	false

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 35,847	$ 70,340
Accounts receivable, net	15,024	13,591
Inventory	9,737	8,899
Current portion of net investments in sales-type leases	968	1,538
Current portion of prepaid commission expense	2,351	1,997
Current portion of notes receivable	1,850	230
Prepaid expenses and other current assets	5,234	2,174
Total current assets	71,011	98,769
Property and equipment, net	2,066	1,991
Operating lease right-of-use assets	2,916	3,327
Net investments in sales-type leases	700	1,222
Prepaid commission expense	8,018	7,568
Long-term notes receivable	4,191	362
Other assets	4,086	3,645
Total Assets	92,988	116,884
Current liabilities:
Accounts payable	2,822	2,433
Accrued expenses	10,037	14,837
Deferred revenue	1,637	1,980
Current portion of operating lease liabilities	840	824
Current portion of long-term debt, net		13,125
Total current liabilities	15,336	33,199
Long-term debt, net	36,851	22,829
Deferred revenue	354	829
Operating lease liabilities	2,506	2,967
Total Liabilities	55,047	59,824
Commitments and contingencies (Note 17)
Stockholders' Equity:
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on September 30, 2023, and December 31, 2022
Common stock, $0.01 par value: 200,000 shares authorized; 28,902 and 27,268 shares issued and outstanding on September 30, 2023, and December 31, 2022, respectively	289	273
Additional paid-in capital	408,356	402,679
Accumulated deficit	(370,704)	(345,892)
Total Stockholders' Equity	37,941	57,060
Total Liabilities and Stockholders' Equity	$ 92,988	$ 116,884

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Sep. 30, 2023	Dec. 31, 2022
Balance Sheets
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200,000	200,000
Common stock, shares issued	28,902	27,268
Common stock, shares outstanding	28,902	27,268

Statements of Operations

Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statements of Operations
Revenues	$ 17,884	$ 16,498	$ 51,034	$ 47,008
Cost of revenues	6,120	3,570	15,100	11,093
Gross Profit	11,764	12,928	35,934	35,915
Operating expenses:
Sales and marketing	12,141	11,643	35,602	37,977
General and administrative	6,339	6,391	19,151	19,125
Research and development	2,155	2,348	7,308	6,197
Total operating expenses	20,635	20,382	62,061	63,299
Loss from operations	(8,871)	(7,454)	(26,127)	(27,384)
Other (income) expense:
Interest expense	1,184	1,061	3,580	3,039
Other income, net	(664)	(906)	(4,895)	(1,554)
Net Loss	$ (9,391)	$ (7,609)	$ (24,812)	$ (28,869)
Net loss per share of common stock outstanding, basic	$ (0.33)	$ (0.28)	$ (0.87)	$ (1.08)
Net loss per share of common stock outstanding, diluted	$ (0.33)	$ (0.28)	$ (0.87)	$ (1.08)
Weighted-average common shares outstanding, basic	28,876	26,965	28,505	26,797
Weighted-average common shares outstanding, diluted	28,876	26,965	28,505	26,797

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2021	$ 264	$ 393,644	$ (308,733)	$ 85,175
Beginning balance, shares at Dec. 31, 2021	26,395
Share-based awards and options exercises	$ 3	6		9
Share-based awards and options exercises, shares	322
Share-based compensation expense		2,252		2,252
Net Loss			(10,838)	(10,838)
Ending balance at Mar. 31, 2022	$ 267	395,902	(319,571)	76,598
Ending balance, shares at Mar. 31, 2022	26,717
Beginning balance at Dec. 31, 2021	$ 264	393,644	(308,733)	85,175
Beginning balance, shares at Dec. 31, 2021	26,395
Net Loss				(28,869)
Ending balance at Sep. 30, 2022	$ 270	400,323	(337,602)	62,991
Ending balance, shares at Sep. 30, 2022	27,060
Beginning balance at Mar. 31, 2022	$ 267	395,902	(319,571)	76,598
Beginning balance, shares at Mar. 31, 2022	26,717
Share-based awards and options exercises	$ 1	42		43
Share-based awards and options exercises, shares	139
Share-based compensation expense		2,203		2,203
Net Loss			(10,422)	(10,422)
Ending balance at Jun. 30, 2022	$ 268	398,147	(329,993)	68,422
Ending balance, shares at Jun. 30, 2022	26,856
Share-based awards and options exercises	$ 2	(2)
Share-based awards and options exercises, shares	204
Share-based compensation expense		2,178		2,178
Net Loss			(7,609)	(7,609)
Ending balance at Sep. 30, 2022	$ 270	400,323	(337,602)	62,991
Ending balance, shares at Sep. 30, 2022	27,060
Beginning balance at Dec. 31, 2022	$ 273	402,679	(345,892)	57,060
Beginning balance, shares at Dec. 31, 2022	27,268
Share-based awards and options exercises	$ 12	(12)
Share-based awards and options exercises, shares	1,197
Share-based compensation expense		1,805		1,805
Net Loss			(10,520)	(10,520)
Ending balance at Mar. 31, 2023	$ 285	404,472	(356,412)	48,345
Ending balance, shares at Mar. 31, 2023	28,465
Beginning balance at Dec. 31, 2022	$ 273	402,679	(345,892)	57,060
Beginning balance, shares at Dec. 31, 2022	27,268
Net Loss				(24,812)
Ending balance at Sep. 30, 2023	$ 289	408,356	(370,704)	37,941
Ending balance, shares at Sep. 30, 2023	28,902
Beginning balance at Mar. 31, 2023	$ 285	404,472	(356,412)	48,345
Beginning balance, shares at Mar. 31, 2023	28,465
Share-based awards and options exercises	$ 3	(3)
Share-based awards and options exercises, shares	348
Share-based compensation expense		2,033		2,033
Net Loss			(4,901)	(4,901)
Ending balance at Jun. 30, 2023	$ 288	406,502	(361,313)	45,477
Ending balance, shares at Jun. 30, 2023	28,813
Share-based awards and options exercises	$ 1	(1)
Share-based awards and options exercises, shares	89
Share-based compensation expense		1,855		1,855
Net Loss			(9,391)	(9,391)
Ending balance at Sep. 30, 2023	$ 289	$ 408,356	$ (370,704)	$ 37,941
Ending balance, shares at Sep. 30, 2023	28,902

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended	9 Months Ended		12 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash Flows from Operating Activities:
Net loss		$ (24,812)	$ (28,869)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,503	1,044
Allowance for credit losses		369	328
Inventory impairment	$ 1,900	1,905
Share-based compensation		5,693	6,633
Non-cash interest expense		460	513
Cost of rental units purchased by customers			92
Changes in certain assets and liabilities:
Accounts receivable, net		(7,933)	(4,585)
Inventory		(2,742)	(2,299)
Net investments in sales-type leases		1,092	381
Prepaid commission expense		(804)	(854)
Prepaid expenses and other assets		(3,338)	176
Accounts payable		54	(2,199)
Accrued expenses		(4,801)	3,260
Deferred revenue		(817)	(1,260)
Net Cash Used in Operating Activities		(34,171)	(27,639)	$ (30,700)
Cash Flows from Investing Activities:
Purchases of property and equipment and capitalized software		(1,490)	(2,766)
Repayment of notes receivable		731	10,000
Net Cash (Used in) Provided by Investing Activities		(759)	7,234
Cash Flows from Financing Activities:
Payments of debt issuance costs		(863)	(90)
Proceeds from issuance of long-term debt		2,500
Repayment of long-term debt		(1,200)
Proceeds from exercises of stock options			52
Net Cash Provided by (Used in) Financing Activities		437	(38)
Net Decrease in Cash and Cash Equivalents		(34,493)	(20,443)
Cash and Cash Equivalents, Beginning of Period		70,340	94,141	94,141
Cash and Cash Equivalents, End of Period	$ 35,847	35,847	73,698	$ 70,340
Supplemental disclosure of cash flow information:
Cash paid for interest		3,120	2,525
Transfer of inventory to property and equipment			285
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment and capitalized software in accounts payable and accrued expenses		335	$ 251
Reduction of accounts receivable in current and long-term notes receivable		$ 6,330

Description of Business

Description of Business	9 Months Ended
Description of Business	Sep. 30, 2023
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1. DESCRIPTION OF BUSINESS Neuronetics, Inc. (the “Company”) is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The Company’s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (“TMS”) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system was cleared in 2008 by the United States (“U.S.”) Food and Drug Administration (the “FDA”) to treat adult patients with major depressive disorder (“MDD”) who have failed to achieve satisfactory improvement from prior antidepressant medication in the current MDD episode. The NeuroStar Advanced Therapy System is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. The Company intends to continue to pursue development of the NeuroStar Advanced Therapy System for additional indications. Liquidity As of September 30, 2023, the Company had cash and cash equivalents of $35.8 million and an accumulated deficit of $370.7 million. The Company incurred negative cash flows from operating activities of $34.2 million for the nine months ended September 30, 2023 and $30.7 million for the year ended December 31, 2022. The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company continues to invest in sales, marketing and product development activities. The Company’s primary sources of capital to date have been proceeds from its initial public offering (“IPO”), private placements of its convertible preferred securities, borrowings under its credit facility, proceeds from its secondary public offering of common stock and revenues from sales of its products. As of September 30, 2023, the Company had $37.5 million of borrowings outstanding under its credit facility, which has a final maturity in March 2028

Basis of Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	2. BASIS OF PRESENTATION The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) promulgated by the Financial Accounting Standards Board (“FASB”). Interim Financial Statements The accompanying unaudited interim financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the “SEC”), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets and statements of operations and stockholders’ equity and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes that the disclosures are adequate to make the information presented not misleading. Unaudited interim results of operations and cash flows for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company’s Form 10-K filed with the SEC on March 7, 2023, wherein a more complete discussion of significant accounting policies and certain other information can be found. Use of Estimates The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes that its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions, and given the subjective element of the estimates and assumptions, actual results may differ materially from estimated results.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company’s complete summary of significant accounting policies can be found in “Note 3. Summary of Significant Accounting Policies” in the audited financial statements included in the Company’s Form 10-K filed with the SEC on March 7, 2023.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2023
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Accounting Pronouncements	4. RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Standards Adopted by the Company In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments “Topic 326” ASU 2019-04, ASU 2019-05, Financial Instruments - Credit Losses (Topic 326) : Targeted Transition Relief , was issued to provide entities that have certain instruments within the scope of ASC 326 with an option to irrevocably elect the fair value option under ASC 825-10, Financial Instruments - Overall , applied on an instrument-by-instrument basis for eligible instruments ASU 2019-10, Topic 326, Topic 815, and Topic 842 amend the mandatory effective date for Topic 326. The Company adopted Topic 326 with an adoption date of January 1, 2023 using the modified retrospective approach. As a result, the Company changed its accounting policy for allowance for credit losses. The Company monitors accounts receivable and long-term notes receivable and estimates the allowance for lifetime expected credit losses. Estimates of expected credit losses are based on historical collection experience and other factors, including those related to current market conditions and events. The adoption did not have a material effect on the Company's financial statements. Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our unaudited interim financial statements.

Fair Value Measurement and Fina

Fair Value Measurement and Financial Instruments	9 Months Ended
Fair Value Measurement and Financial Instruments	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurement and Financial Instruments	5. FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS The carrying values of cash equivalents, accounts receivable, prepaids and other current assets, and accounts payable on the Company’s balance sheets approximated their fair values as of September 30, 2023 and December 31, 2022 due to their short-term nature. The carrying values of the Company’s credit facility approximated its fair value as of September 30, 2023 and December 31, 2022 due to its variable interest rate. The carrying value of the Company’s notes receivable approximated its fair value as of September 30, 2023 and December 31, 2022 due to its variable interest rate. Certain of the Company’s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 Inputs are quoted prices for identical instruments in active markets. Level 2 Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 Inputs are unobservable and reflect the Company’s own assumptions, based on the best information available, including the Company’s own data . The following tables set forth the carrying amounts and fair values of the Company’s financial instruments as of September 30, 2023 and December 31, 2022 (in thousands): September 30, 2023 Fair Value Measurement Based on Quoted Significant Prices In other Significant Active Observable Unobservable Carrying Markets Inputs Inputs Amount Fair Value (Level 1) (Level 2) (Level 3) Assets Money market funds (cash equivalents) $ 27,163 $ 27,163 $ 27,163 $ — $ — December 31, 2022 Fair Value Measurement Based on Quoted Significant Prices In other Significant Active Observable Unobservable Carrying Markets Inputs Inputs Amount Fair Value (Level 1) (Level 2) (Level 3) Assets Money market funds (cash equivalents) $ 68,002 $ 68,002 $ 68,002 $ — $ —

Accounts Receivable

Accounts Receivable	9 Months Ended
Accounts Receivable	Sep. 30, 2023
Receivables [Abstract]
Accounts Receivable	6. ACCOUNTS RECEIVABLE The following table presents the composition of accounts receivable, net as of September 30, 2023 and December 31, 2022 (in thousands): September 30, December 31, 2023 2022 Gross accounts receivable - trade $ 16,155 $ 15,239 Less: Allowances for credit losses (1,131) (1,648) Accounts receivable, net $ 15,024 $ 13,591

Inventory

Inventory	9 Months Ended
Inventory	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventory	7. INVENTORY Inventory is stated at the lower of cost and net realizable value, with cost being determined on a first in, first out basis. The Company’s inventory is primarily comprised of finished goods. During the three months ended September 30, 2023, the Company recorded a $1.9 million inventory impairment for specialized component parts secured for discontinued NeuroStar Advanced Therapy Systems whose cost exceeds net realizable value.

Property and Equipment and Capi

Property and Equipment and Capitalized Software	9 Months Ended
Property and Equipment and Capitalized Software	Sep. 30, 2023
Property Plant And Equipment Abstract [Abstract]
Property and Equipment and Capitalized Software	8. PROPERTY AND EQUIPMENT AND CAPITALIZED SOFTWARE The following table presents the composition of property and equipment, net as of September 30, 2023 and December 31, 2022 (in thousands): September 30, December 31, 2023 2022 Laboratory equipment $ 666 $ 462 Office equipment 510 508 Computer equipment and software 1,966 1,758 Manufacturing equipment 485 343 Leasehold improvements 1,442 1,435 Rental equipment 542 542 Property and equipment, gross 5,611 5,048 Less: Accumulated depreciation (3,545) (3,057) Property and equipment, net $ 2,066 $ 1,991 As of September 30, 2023 and December 31, 2022, the Company had capitalized software costs, net of $3.9 million and $3.6 million, respectively, which are included in “Prepaid expenses and other current assets” and “Other assets” on the balance sheet. Depreciation and amortization expense was $0.5 million and $0.4 million for the three months ended September 30, 2023 and 2022, respectively, and $1.5 million and $1.0 million for the nine months ended September 30, 2023 and 2022, respectively.

Notes Receivable

Notes Receivable	9 Months Ended
Notes Receivable	Sep. 30, 2023
Accounts Notes, Loans And Financing, Receivable, Gross, Allowance, And Net [Abstract]
Notes Receivable	9. NOTES RECEIVABLE Greenbrook TMS Inc. On March 31, 2023, the Company entered into a Secured Promissory Note and Guaranty Agreement (the “Promissory Note”) with TMS Neurohealth Centers Inc. (the “Maker”) and Greenbrook TMS Inc. and its subsidiaries, excluding the Maker (the “Guarantors”), in the principal amount of $6.0 million for a period of four years. The Promissory Note will bear interest at a rate equal to the sum of (a) the floating interest rate of daily secured overnight financing rate as administered by the Federal Reserve Bank of New York on its website (“SOFR”) plus (b) 7.65%. Pursuant to the terms of the Promissory Note, in the event of an event of default thereunder, the Maker will be required to issue common share purchase warrants to the Company equal to (i) 200% of the unpaid amount of any delinquent amount or payment due and payable under the Promissory Note, together with all outstanding and unpaid accrued interest, fees, charges and costs, divided by (ii) the exercise price of the warrants, which will represent a 20% discount to the 30-day volume-weighted average closing price of Greenbrook TMS Inc.’s common shares traded on the Nasdaq Stock Market (“Nasdaq”) prior to the date of issuance (subject to any limitations that may be required by Nasdaq). Under the Promissory Note and related loan documents, the Maker and the Guarantors have granted to the Company a security interest in substantially all of the Maker’s and the Guarantors’ assets and the Guarantors have guaranteed the Maker’s obligations under the Promissory Note. The Company’s security interest pursuant to the Promissory Note and related loan documents ranks pari passu with the Maker’s senior lender, Madryn Fund Administration, LLC, and is subject to an intercreditor agreement. Success TMS On September 29, 2021, the Company entered into an exclusive, five-year master sales agreement with Check Five LLC doing business as Success TMS (“Success TMS”). In connection with the Commercial Agreement, the Company agreed to loan Success TMS the principal amount of $10.0 million for a period of five years pursuant to a secured promissory note (the “Note”). On July 14, 2022, Success TMS repaid in full the Note with a cash payment of $10.5 million, which included all outstanding principal, prepayment premium and accrued but unpaid interest. The repayment extinguished the Note in its entirety and terminated the Subordination Agreement entered into by the Company. Interest income recognized by the Company related to notes receivable was $0.2 million and $0.5 million for the three months ended September 30, 2023 and 2022, respectively. Interest income recognized by the Company related to notes receivable was $0.4 million and $1.0 million for the nine months ended September 30, 2023 and 2022, respectively. September 30, December 31, 2023 2022 Current portion of notes receivable $ 1,890 $ 230 Long-term notes receivable 4,299 362 Less: Allowances for credit losses (148) — Notes receivable, net $ 6,041 $ 592

Leases

Leases	9 Months Ended
Leases	Sep. 30, 2023
Leases [Abstract]
Leases	10. LEASES Lessee: The Company has operating leases for its corporate headquarters, a training facility and office equipment, including copiers. The Company leases an approximately 32,000 square foot facility in Malvern, Pennsylvania for its corporate headquarters, which includes office and warehouse space. The Company leases an approximately 9,600 square foot facility in Charlotte, North Carolina as a training facility for its NeuroStar Advanced Therapy Systems. The Company does not currently have any finance leases or executed leases that have not yet commenced. Operating lease rent expense was $0.2 million for the three months ended September 30, 2023 and 2022, and $0.6 million for the nine months ended September 30, 2023 and 2022. As of September 30, 2023, the weighted-average remaining lease term of operating leases was 4.3 years and the weighted-average discount rate was 7.2%. The following table presents the supplemental cash flow information as a lessee related to leases (in thousands): Nine Months Ended September 30, 2023 September 30, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 807 $ 632 The following table sets forth by year the required future payments of operating lease liabilities (in thousands): September 30, 2023 Remainder of 2023 $ 215 2024 875 2025 898 2026 921 2027 882 2028 116 Total lease payments 3,907 Less imputed interest (561) Present value of operating lease liabilities $ 3,346 Lessor sales-type leases: Certain customers have purchased NeuroStar Advanced Therapy Systems on a rent-to-own basis. The lease term is three The following table sets forth the profit recognized on sales-type leases (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Profit recognized at commencement, net $ 13 $ 122 $ 60 $ 543 Interest income — — — — Total sales-type lease income $ 13 $ 122 $ 60 $ 543 The following table sets forth a maturity analysis of the undiscounted lease receivables related to sales-type leases (in thousands): September 30, 2023 Remainder of 2023 $ 298 2024 876 2025 390 2026 76 2027 28 Total sales-type lease receivables $ 1,668 As of September 30, 2023, the carrying amount of the lease receivables is $1.7 million. The Company does not have any unguaranteed residual assets. Lessor operating leases: NeuroStar Advanced Therapy Systems sold for which collection is not probable are accounted for as operating leases. For the three months ended September 30, 2023 and 2022, the Company recognized operating lease income of $0.02 million and $0.07 million, respectively. For the nine months ended September 30, 2023 and 2022, the Company recognized operating lease income of $0.1 million and $0.2 million, respectively. The Company maintained rental equipment, net of $0.4 million and $0.5 million as of September 30, 2023 and December 31, 2022, respectively, which are included in “Property and equipment, net” on the balance sheet. Rental equipment depreciation expense was $0.02 million for the three months ended September 30, 2023 and 2022, and $0.07 million for the nine months ended September 30, 2023 and 2022, respectively.

Prepaid Commission Expense

Prepaid Commission Expense	9 Months Ended
Prepaid Commission Expense	Sep. 30, 2023
Amortization Of Deferred Charges [Abstract]
Prepaid Commission Expense	11. PREPAID COMMISSION EXPENSE The Company pays a commission on both NeuroStar Advanced Therapy System sales and treatment session sales. Since the commission paid for system sales is not commensurate with the commission paid for treatment sessions, the Company capitalizes commission expense associated with NeuroStar Advanced Therapy System sales commissions paid that is incremental to specifically anticipated future treatment session orders. In developing this estimate, the Company considered its historical treatment session sales and customer retention rates, as well as technology development life cycles and other industry factors. These costs are periodically reviewed for impairment. NeuroStar Advanced Therapy System commissions are deferred and amortized on a straight-line basis over a seven-year period equal to the average customer term, which the Company deems to be the expected period of benefit for these costs. On the Company’s balance sheets, the current portion of capitalized contract costs is represented by the current portion of prepaid commission expense, while the long-term portion is included in prepaid commission expense. Amortization expense was $0.6 million and $0.5 million for the three months ended September 30, 2023 and 2022, respectively, and $1.7 million and $1.3 million for the nine months ended September 30, 2023 and 2022, respectively.

Accrued Expenses

Accrued Expenses	9 Months Ended
Accrued Expenses	Sep. 30, 2023
Payable And Accruals [Abstract]
Accrued Expenses	12. ACCRUED EXPENSES The following table presents the composition of accrued expenses as of September 30, 2023 and December 31, 2022 (in thousands): September 30, December 31, 2023 2022 Compensation and related benefits $ 6,342 $ 11,201 Consulting and professional fees 713 761 Research and development expenses 278 678 Sales and marketing expenses 1,012 410 Warranty 198 328 Sales and other taxes payable 641 659 Other 853 800 Accrued expenses $ 10,037 $ 14,837

Deferred Revenue

Deferred Revenue	9 Months Ended
Deferred Revenue	Sep. 30, 2023
Deferred Revenue [Abstract]
Deferred Revenue	13. DEFERRED REVENUE Payment terms typically require payment upon shipment or installation of the NeuroStar Advanced Therapy System and additional payments as access codes for treatment sessions are delivered, which can span several years after the system is first delivered and installed. The timing of revenue recognition compared to billings and cash collections typically results in accounts receivable. However, sometimes customer advances and deposits may be required for certain customers and are recorded as contract liabilities (deferred revenue). For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual coverage period and recognizes revenue over the term of the coverage period. As of September 30, 2023, the Company expects to recognize approximately the following percentages of deferred revenue by year: Revenue Year: Recognition Remainder of 2023 29 % 2024 59 % 2025 11 % 2026 1 % Total 100 % Revenue recognized for the three months ended September 30, 2023 and 2022 that was included in the contract liability balance at the beginning of the year was $0.4 million. Revenue recognized for the nine months ended September 30, 2023 and 2022 that was included in the contract liability balance at the beginning of the year was $1.7 million and $2.2 million, respectively, and primarily represented revenue earned from separately priced extended warranties, customer deposits, milestone revenue, and clinical training. Customers Significant customers are those that represent more than 10% of the Company’s total revenue. For the three months ended September 30, 2023 and 2022, one customer accounted for 15% and 15% of the Company’s revenue, respectively. For the nine months ended September 30, 2023 and 2022, one customer accounted for 17% and 16% of the Company’s revenue, respectively. Accounts receivable outstanding related to the customer was $2.1 million and $5.2 million as of September 30, 2023 and December 31, 2022, respectively. Geographical information The following geographic data includes revenue generated from the Company’s third-party distributors. The Company’s revenue was generated in the following geographic regions and by product line for the periods indicated (in thousands): Revenues by Geography Three Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) U.S. $ 17,211 96 % $ 16,244 98 % International 673 4 % 254 2 % Total revenues $ 17,884 100 % $ 16,498 100 % U.S. Revenues by Product Category Three Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 3,597 21 % $ 3,934 24 % Treatment sessions 13,060 76 % 11,864 73 % Other 554 3 % 446 3 % Total U.S. revenues $ 17,211 100 % $ 16,244 100 % International Revenues by Product Category Three Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 258 38 % $ 96 38 % Treatment sessions 280 42 % 31 12 % Other 135 20 % 127 50 % Total international revenues $ 673 100 % $ 254 100 % Revenues by Geography Nine Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) U.S. $ 49,464 97 % $ 45,893 98 % International 1,570 3 % 1,115 2 % Total revenues $ 51,034 100 % $ 47,008 100 % U.S. Revenues by Product Category Nine Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 11,936 24 % $ 11,959 26 % Treatment sessions 36,018 73 % 32,627 71 % Other 1,510 3 % 1,307 3 % Total U.S. revenues $ 49,464 100 % $ 45,893 100 % International Revenues by Product Category Nine Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 573 36 % $ 460 41 % Treatment sessions 589 38 % 214 19 % Other 408 26 % 441 40 % Total International revenues $ 1,570 100 % $ 1,115 100 %

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	14. DEBT The following table presents the composition of debt as of September 30, 2023 and December 31, 2022 (in thousands): September 30, December 31, 2023 2022 Outstanding principal $ 37,500 $ 35,000 Accrued final payment fees 1,856 1,925 Less debt discounts (2,505) (971) Total debt, net 36,851 35,954 Less current portion — (13,125) Long-term debt, net $ 36,851 $ 22,829 For the three months ended September 30, 2023, the Company recognized interest expense of $1.2 million, of which $1.1 million was cash and $0.1 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. For the three months ended September 30, 2022, the Company recognized interest expense of $1.1 million, of which $0.9 million was cash and $0.2 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. For the nine months ended September 30, 2023, the Company recognized interest expense of $3.6 million, of which $3.1 million was cash and $0.5 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. For the nine months ended September 30, 2022, the Company recognized interest expense of $3.0 million, of which $2.5 million was cash and $0.5 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. Solar Credit Facility Solar Facility Fourth and Fifth Amendments On March 29, 2023, the Company entered into a fourth amendment (the “Solar Fourth Amendment”) to the Loan and Security Agreement dated March 2, 2020 with SLR Investment Corp. (formerly known as Solar Capital Ltd.) (“Solar”), as collateral agent and other lenders as defined in the agreement (the “Lenders”; such agreement, as amended, the “Solar Facility”). On September 29, 2023, the Company entered into a fifth amendment (the “Solar Fifth Amendment”) to the Solar Facility. The Solar Facility permits the Company to borrow up to $60.0 million in three tranches of term loans, a “Term A Loan” in an aggregate amount of $35.0 million, a “Term B Loan” in an aggregate amount of $2.5 million, and a “Term C Facility” (collectively with the Term A Loan and Term B Loan, the “Loans”) in an aggregate principal amount equal to $22.5 million. The Term A Loan was fully drawn prior to the effectiveness of the Solar Fourth Amendment. On March 29, 2023, the Company borrowed an amount of $2.5 million under the Term B Loan. On October 3, 2023, the Company borrowed an amount of $22.5 million under the Term C Facility (the “Term C Funding Date”). The maturity date of the Loans is March 29, 2028. Prior to the effectiveness of the Solar Fourth Amendment, the maturity date of the Term A Loan was February 28, 2025. The Loans accrue interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which resets monthly and is equal to the greater of 5.65% plus (a) 3.95% or (b) daily simple SOFR for a term of one month. Only interest is required to be paid on the Loans until March 1, 2026. Prior to the effectiveness of the Solar Fourth Amendment, the interest only period with respect to the Term A Loan expired on March 1, 2023. Commencing April 1, 2026, the Company will be required to make monthly payments of principal and interest on the Loans. In addition to the principal and interest payments due under the Solar Facility, the Company is required to pay a final payment fee to Solar upon the earlier of prepayment, acceleration or the maturity date of the Loans equal to 4.95% of the principal amount of the term loans actually funded. If the Company prepays the Loans prior to their respective scheduled maturities, the Company will also be required to pay prepayment fees to Solar equal to 3% of the principal amount of such term loan then-prepaid if prepaid on or before the first anniversary of the Term C Funding Date, 2% of the principal amount of such term loan then-prepaid if prepaid after the first anniversary and on or before the second anniversary of the Term C Funding Date, or 1% of the principal amount of such term loan then-prepaid if prepaid after the second anniversary of the Term C Funding Date. The Company is also required to pay Solar an exit fee upon the occurrence of (a) any liquidation, dissolution or winding up of the Company, (b) any transaction that results in a person obtaining control over the Company, (c) the Company achieving $100 million in trailing twelve-month net product revenue or (d) the Company achieving $125 million in trailing twelve-month net product revenue. The exit fee for liquidation, dissolution, winding up or change of control of the Company is equal to 2% of the principal amount of the term loans actually funded. The exit fee for achieving either $100 million or $125 million in trailing twelve-month net product revenue is equal to 1% of the principal amount of the term loans actually funded or, if both net product revenue milestones are achieved, 2% of the principal amount of the term loans actually funded. The exit fee is capped at 2% of the principal amount of the term loans actually funded. In connection with entering into the Solar Fourth Amendment and pursuant to the prepayment provisions of the previous Solar facility, the Company paid Solar a final payment fee of $1.2 million on March 29, 2023. The Solar Fifth Amendment (a) permitted the Company to draw on the $22.5 million Term C Facility, and (b) revised the required testing levels of the net product revenue and minimum liquidity covenants for certain testing periods. As of September 30, 2023, the Company was in compliance with all covenants in the Solar Facility, and the Company expects to be in compliance with the covenants going forward.

Common Stock

Common Stock	9 Months Ended
Common Stock	Sep. 30, 2023
Equity [Abstract]
Common Stock	15. COMMON STOCK Common Stock The following table summarizes the total number of shares of the Company’s common stock issued and reserved for issuance as of September 30, 2023 and December 31, 2022 (in thousands): September 30, 2023 December 31, 2022 Shares of common stock issued 28,902 27,268 Shares of common stock reserved for issuance for: Common stock warrants outstanding 41 61 Stock options outstanding 1,271 1,301 Restricted stock units outstanding 3,634 3,901 Shares available for grant under stock incentive plans 893 1,140 Shares available for sale under employee stock purchase plan 1,335 1,063 Total shares of common stock issued and reserved for issuance 36,076 34,734 Common Stock Warrants The following tables summarize the Company’s outstanding common stock warrants as of September 30, 2023, and December 31, 2022: September 30, 2023 Warrants Outstanding (in thousands) Exercise Price Expiration Date 20 $ 9.73 Mar-2024 21 $ 9.73 Dec-2024 41 December 31, 2022 Warrants Outstanding (in thousands) Exercise Price Expiration Date 20 $ 9.73 Aug-2023 20 $ 9.73 Mar-2024 21 $ 9.73 Dec-2024 61

Loss Per Share

Loss Per Share	9 Months Ended
Loss Per Share	Sep. 30, 2023
Earnings Per Share [Abstract]
Loss Per Share	16. LOSS PER SHARE The Company’s basic loss per common share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. The Company’s restricted stock awards (non-vested shares) are issued and outstanding at the time of grant but are excluded from the Company’s computation of weighted-average shares outstanding in the determination of basic loss per share until vesting occurs. A net loss cannot be diluted, so when the Company is in a net loss position, basic and diluted loss per common share are the same. If in the future the Company achieves profitability, the denominator of a diluted earnings per common share calculation will include both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options, non-vested restricted stock units and non-vested performance restricted stock units (“PRSUs”) using the treasury stock method, along with the effect, if any, from the potential conversion of outstanding securities, such as convertible preferred stock. The following potentially dilutive securities outstanding as of September 30, 2023 and 2022 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands): September 30, 2023 2022 Stock options 1,271 1,424 Non-vested PRSUs 395 395 Non-vested restricted stock units 3,239 3,665 Common stock warrants 41 75

Share-Based Compensation

Share-Based Compensation	9 Months Ended
Share-Based Compensation	Sep. 30, 2023
Disclosure Of Compensation Related Costs Share-based Payments [Abstract]
Share-Based Compensation	17. SHARE-BASED COMPENSATION The amount of share-based compensation expense recognized by the Company by location in its statements of operations for the three and nine months ended September 30, 2023 and 2022 is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of revenues $ 38 $ 35 $ 109 94 Sales and marketing 590 1,074 1,946 3,258 General and administrative 1,052 939 3,134 2,950 Research and development 175 130 504 331 Total $ 1,855 $ 2,178 $ 5,693 $ 6,633 2018 Equity Incentive Plan In June 2018, the Company adopted the 2018 Equity Incentive Plan, (the “2018 Plan”), which authorized the issuance of up to 1.4 million shares, subject to an annual 4% increase based on the number of shares of common stock outstanding, in the form of restricted stock, stock appreciation rights and stock options to the Company’s directors, employees and consultants. The amount and terms of grants are determined by the Company’s board of directors. All stock options granted to date have had exercise prices equal to the fair value, as determined by the closing price as reported by the Nasdaq Global Market, of the underlying common stock on the date of grant. The contractual term of stock options is up to 10 years, and stock options are exercisable in cash or as otherwise determined by the Company’s board of directors. Generally, stock options vest 25% upon the first anniversary of the date of grant and the remainder ratably monthly thereafter for 36 months. Restricted stock units generally vest ratably in three equal installments on the first, second and third anniversaries of the grant date. PRSUs generally vest based on appreciation of the Company’s common stock to a certain price as determined by the Company’s board of directors measured using a trailing 30-day volume-weighted average price of a share of the Company’s common stock. The fair value of the PRSU awards are determined using a risk neutral Monte Carlo simulation valuation model. As of September 30, 2023, there were 0.6 million shares available for future issuance under the 2018 Plan. 2020 Inducement Incentive Plan In December 2020, the Company adopted the 2020 Inducement Incentive Plan (the “2020 Plan”), which authorized the issuance of up to 0.4 million shares, subject to increase by approval of the Company’s board of directors, in the form of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards and other stock awards to eligible employees who satisfy the standards for inducement grants under Nasdaq Global Market rules. In March 2022, the Company’s board of directors approved an additional 0.5 million shares for the issuance under the 2020 Plan. An individual who previously served as an employee or director of the Company is not eligible to receive awards under the 2020 Plan. The amount and terms of grants are determined by the Company’s board of directors. As of September 30, 2023, there were 0.3 million shares available for future issuance under the 2020 Plan. Stock Options The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2023: Weighted- Aggregate Number of Weighted- average average Shares under average Remaining Intrinsic Option Exercise Price Contractual Value (in thousands) per Option Life (in years) (in thousands) Outstanding at December 31, 2022 1,301 $ 4.07 Granted — $ — Exercised — $ — Forfeited (30) $ 11.67 Outstanding at September 30, 2023 1,271 $ 3.89 6.3 $ 3 Exercisable at September 30, 2023 1,058 $ 4.27 6.3 $ 3 Vested and expected to vest at September 30, 2023 1,271 $ 3.89 6.3 $ 3 The Company recognized share-based compensation expense related to stock options of $0.1 million and $0.2 million for the three months ended September 30, 2023 and 2022, respectively, and $0.3 million and $0.5 million for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, there was $0.2 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 0.8 years. For the nine months ended September 30, 2023 the Company did not grant stock options. Restricted Stock Units and Performance Restricted Stock Units The following table summarizes the Company’s restricted stock unit and PRSU activity for September 30, 2023: Non-vested Weighted- Non-vested Weighted- Restricted average PRSUs average Stock Units Grant-date Grant-date (in thousands) Fair Value (in thousands) Fair Value Non-vested at December 31, 2022 3,506 $ 4.29 395 $ 6.77 Granted 1,640 $ 4.73 — $ — Vested (1,634) $ 4.38 — $ — Forfeited (273) $ 5.08 — $ — Non-vested at September 30, 2023 3,239 $ 4.41 395 $ 6.77 The Company recognized $1.8 million and $2.0 million in share-based compensation expense related to the restricted stock units and PRSUs for the three months ended September 30, 2023 and 2022, respectively, and $5.3 million and $6.1 million for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, there was $10.0 million of unrecognized compensation cost related to non-vested restricted stock units and PRSUs, which the Company expects to recognize over a weighted-average period of 1.8 years. The total fair value at the vesting date of restricted stock units and PRSUs vested during the nine months ended September 30, 2023 was $8.3 million. The Company did not grant PRSUs during the nine months ended September 30, 2023.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2023
Commitments And Contingencies Disclosure[Abstract]
Commitments and Contingencies	18. COMMITMENTS AND CONTINGENCIES Legal Matters The Company is subject from time to time to various claims and legal actions arising during the ordinary course of its business. Management believes that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on the Company’s results of operations, financial condition, or cash flows.

Segment Information

Segment Information	9 Months Ended
Segment Information	Sep. 30, 2023
Segments Geographical Areas [Abstract]
Segment Information	19. SEGMENT INFORMATION Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company currently operates in one business segment as it is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. The Company does not operate any material separate lines of business or separate business entities with respect to its products or product development.

Government Assistance

Government Assistance	9 Months Ended
Government Assistance	Sep. 30, 2023
Government Assistance [Abstract]
Government Assistance	20. GOVERNMENT ASSISTANCE Employee Retention Credit The Coronavirus Aid, Relief and Economic Security Act provided an Employee Retention Credit (the “ERC”), which was a refundable tax credit related to certain payroll taxes. The Company applied the grant model and determined that the criteria for recognition of the ERC was met during the quarter ended June 30, 2023 based on the Company’s determination of eligibility and filing of the ERC claim. As of September 30, 2023, the $2.9 million ERC receivable is reported within prepaid expenses and other current assets on the Company’s balance sheet. The credit is reported within other income, net in the Company’s statements of operations for the nine months ended September 30, 2023.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2023
Accounting Policies [Abstract]
Interim Financial Statements	Interim Financial Statements The accompanying unaudited interim financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the “SEC”), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets and statements of operations and stockholders’ equity and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes that the disclosures are adequate to make the information presented not misleading. Unaudited interim results of operations and cash flows for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company’s Form 10-K filed with the SEC on March 7, 2023, wherein a more complete discussion of significant accounting policies and certain other information can be found.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes that its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions, and given the subjective element of the estimates and assumptions, actual results may differ materially from estimated results.

Fair Value Measurement and Fi_2

Fair Value Measurement and Financial Instruments (Tables)	9 Months Ended
Fair Value Measurement and Financial Instruments (Tables)	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Carrying Amounts and Fair Values of Financial Instruments	The following tables set forth the carrying amounts and fair values of the Company’s financial instruments as of September 30, 2023 and December 31, 2022 (in thousands): September 30, 2023 Fair Value Measurement Based on Quoted Significant Prices In other Significant Active Observable Unobservable Carrying Markets Inputs Inputs Amount Fair Value (Level 1) (Level 2) (Level 3) Assets Money market funds (cash equivalents) $ 27,163 $ 27,163 $ 27,163 $ — $ — December 31, 2022 Fair Value Measurement Based on Quoted Significant Prices In other Significant Active Observable Unobservable Carrying Markets Inputs Inputs Amount Fair Value (Level 1) (Level 2) (Level 3) Assets Money market funds (cash equivalents) $ 68,002 $ 68,002 $ 68,002 $ — $ —

Accounts Receivable (Tables)

Accounts Receivable (Tables)	9 Months Ended
Accounts Receivable (Tables)	Sep. 30, 2023
Receivables [Abstract]
Composition of Accounts Receivable, Net	The following table presents the composition of accounts receivable, net as of September 30, 2023 and December 31, 2022 (in thousands): September 30, December 31, 2023 2022 Gross accounts receivable - trade $ 16,155 $ 15,239 Less: Allowances for credit losses (1,131) (1,648) Accounts receivable, net $ 15,024 $ 13,591

Property and Equipment and Ca_2

Property and Equipment and Capitalized Software (Tables)	9 Months Ended
Property and Equipment and Capitalized Software (Tables)	Sep. 30, 2023
Property Plant And Equipment Abstract [Abstract]
Summary of Composition of Property and Equipment, Net	The following table presents the composition of property and equipment, net as of September 30, 2023 and December 31, 2022 (in thousands): September 30, December 31, 2023 2022 Laboratory equipment $ 666 $ 462 Office equipment 510 508 Computer equipment and software 1,966 1,758 Manufacturing equipment 485 343 Leasehold improvements 1,442 1,435 Rental equipment 542 542 Property and equipment, gross 5,611 5,048 Less: Accumulated depreciation (3,545) (3,057) Property and equipment, net $ 2,066 $ 1,991

Notes Receivables (Tables)

Notes Receivables (Tables)	9 Months Ended
Notes Receivables (Tables)	Sep. 30, 2023
Accounts Notes, Loans And Financing, Receivable, Gross, Allowance, And Net [Abstract]
Schedule of Notes Receivable, Net	September 30, December 31, 2023 2022 Current portion of notes receivable $ 1,890 $ 230 Long-term notes receivable 4,299 362 Less: Allowances for credit losses (148) — Notes receivable, net $ 6,041 $ 592

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Sep. 30, 2023
Leases [Abstract]
Schedule of Supplemental Cash Flow Information as Lessee Related to Leases	The following table presents the supplemental cash flow information as a lessee related to leases (in thousands): Nine Months Ended September 30, 2023 September 30, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 807 $ 632
Schedule of Future Payments of Operating Lease Liabilities	The following table sets forth by year the required future payments of operating lease liabilities (in thousands): September 30, 2023 Remainder of 2023 $ 215 2024 875 2025 898 2026 921 2027 882 2028 116 Total lease payments 3,907 Less imputed interest (561) Present value of operating lease liabilities $ 3,346
Schedule of Profit Recognized on Sales-type Leases	The following table sets forth the profit recognized on sales-type leases (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Profit recognized at commencement, net $ 13 $ 122 $ 60 $ 543 Interest income — — — — Total sales-type lease income $ 13 $ 122 $ 60 $ 543
Schedule of Maturity Analysis of Undiscounted Lease Receivables Related to Sales-type Leases	The following table sets forth a maturity analysis of the undiscounted lease receivables related to sales-type leases (in thousands): September 30, 2023 Remainder of 2023 $ 298 2024 876 2025 390 2026 76 2027 28 Total sales-type lease receivables $ 1,668

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
Accrued Expenses (Tables)	Sep. 30, 2023
Payable And Accruals [Abstract]
Summary of Composition of Accrued Expenses	The following table presents the composition of accrued expenses as of September 30, 2023 and December 31, 2022 (in thousands): September 30, December 31, 2023 2022 Compensation and related benefits $ 6,342 $ 11,201 Consulting and professional fees 713 761 Research and development expenses 278 678 Sales and marketing expenses 1,012 410 Warranty 198 328 Sales and other taxes payable 641 659 Other 853 800 Accrued expenses $ 10,037 $ 14,837

Deferred Revenue (Tables)

Deferred Revenue (Tables)	9 Months Ended
Deferred Revenue (Tables)	Sep. 30, 2023
Summary of Percentages of Deferred Revenue by Year	As of September 30, 2023, the Company expects to recognize approximately the following percentages of deferred revenue by year: Revenue Year: Recognition Remainder of 2023 29 % 2024 59 % 2025 11 % 2026 1 % Total 100 %
Summary of Revenue Generated in Geographic Regions for Years Indicated	Revenues by Geography Three Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) U.S. $ 17,211 96 % $ 16,244 98 % International 673 4 % 254 2 % Total revenues $ 17,884 100 % $ 16,498 100 % Revenues by Geography Nine Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) U.S. $ 49,464 97 % $ 45,893 98 % International 1,570 3 % 1,115 2 % Total revenues $ 51,034 100 % $ 47,008 100 %
U.S.
Summary of Revenue Generated in Product Category for Years Indicated	U.S. Revenues by Product Category Three Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 3,597 21 % $ 3,934 24 % Treatment sessions 13,060 76 % 11,864 73 % Other 554 3 % 446 3 % Total U.S. revenues $ 17,211 100 % $ 16,244 100 % U.S. Revenues by Product Category Nine Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 11,936 24 % $ 11,959 26 % Treatment sessions 36,018 73 % 32,627 71 % Other 1,510 3 % 1,307 3 % Total U.S. revenues $ 49,464 100 % $ 45,893 100 %
International
Summary of Revenue Generated in Product Category for Years Indicated	International Revenues by Product Category Three Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 258 38 % $ 96 38 % Treatment sessions 280 42 % 31 12 % Other 135 20 % 127 50 % Total international revenues $ 673 100 % $ 254 100 % International Revenues by Product Category Nine Months Ended September 30, 2023 2022 % of % of Amount Revenues Amount Revenues (in thousands, except percentages) NeuroStar Advanced Therapy System $ 573 36 % $ 460 41 % Treatment sessions 589 38 % 214 19 % Other 408 26 % 441 40 % Total International revenues $ 1,570 100 % $ 1,115 100 %

Debt (Tables)

Debt (Tables)	9 Months Ended
Debt (Tables)	Sep. 30, 2023
Debt Disclosure [Abstract]
Summary of Composition of Debt	The following table presents the composition of debt as of September 30, 2023 and December 31, 2022 (in thousands): September 30, December 31, 2023 2022 Outstanding principal $ 37,500 $ 35,000 Accrued final payment fees 1,856 1,925 Less debt discounts (2,505) (971) Total debt, net 36,851 35,954 Less current portion — (13,125) Long-term debt, net $ 36,851 $ 22,829

Common Stock (Tables)

Common Stock (Tables)	9 Months Ended
Common Stock (Tables)	Sep. 30, 2023
Equity [Abstract]
Summary of Common Stock Issued and Reserved for Issuance	The following table summarizes the total number of shares of the Company’s common stock issued and reserved for issuance as of September 30, 2023 and December 31, 2022 (in thousands): September 30, 2023 December 31, 2022 Shares of common stock issued 28,902 27,268 Shares of common stock reserved for issuance for: Common stock warrants outstanding 41 61 Stock options outstanding 1,271 1,301 Restricted stock units outstanding 3,634 3,901 Shares available for grant under stock incentive plans 893 1,140 Shares available for sale under employee stock purchase plan 1,335 1,063 Total shares of common stock issued and reserved for issuance 36,076 34,734
Summary of Outstanding Warrants	The following tables summarize the Company’s outstanding common stock warrants as of September 30, 2023, and December 31, 2022: September 30, 2023 Warrants Outstanding (in thousands) Exercise Price Expiration Date 20 $ 9.73 Mar-2024 21 $ 9.73 Dec-2024 41 December 31, 2022 Warrants Outstanding (in thousands) Exercise Price Expiration Date 20 $ 9.73 Aug-2023 20 $ 9.73 Mar-2024 21 $ 9.73 Dec-2024 61

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended
Loss Per Share (Tables)	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Loss Per Share Calculation	The following potentially dilutive securities outstanding as of September 30, 2023 and 2022 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands): September 30, 2023 2022 Stock options 1,271 1,424 Non-vested PRSUs 395 395 Non-vested restricted stock units 3,239 3,665 Common stock warrants 41 75

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
Share-Based Compensation (Tables)	Sep. 30, 2023
Disclosure Of Compensation Related Costs Share-based Payments [Abstract]
Summary of Share-Based Compensation Expense	The amount of share-based compensation expense recognized by the Company by location in its statements of operations for the three and nine months ended September 30, 2023 and 2022 is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of revenues $ 38 $ 35 $ 109 94 Sales and marketing 590 1,074 1,946 3,258 General and administrative 1,052 939 3,134 2,950 Research and development 175 130 504 331 Total $ 1,855 $ 2,178 $ 5,693 $ 6,633
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2023: Weighted- Aggregate Number of Weighted- average average Shares under average Remaining Intrinsic Option Exercise Price Contractual Value (in thousands) per Option Life (in years) (in thousands) Outstanding at December 31, 2022 1,301 $ 4.07 Granted — $ — Exercised — $ — Forfeited (30) $ 11.67 Outstanding at September 30, 2023 1,271 $ 3.89 6.3 $ 3 Exercisable at September 30, 2023 1,058 $ 4.27 6.3 $ 3 Vested and expected to vest at September 30, 2023 1,271 $ 3.89 6.3 $ 3
Summary of Restricted Stock Units and Performance Restricted Stock Units Activity	The following table summarizes the Company’s restricted stock unit and PRSU activity for September 30, 2023: Non-vested Weighted- Non-vested Weighted- Restricted average PRSUs average Stock Units Grant-date Grant-date (in thousands) Fair Value (in thousands) Fair Value Non-vested at December 31, 2022 3,506 $ 4.29 395 $ 6.77 Granted 1,640 $ 4.73 — $ — Vested (1,634) $ 4.38 — $ — Forfeited (273) $ 5.08 — $ — Non-vested at September 30, 2023 3,239 $ 4.41 395 $ 6.77

Description of Business - Addit

Description of Business - Additional Information (Details) - USD ($) $ in Thousands		9 Months Ended		12 Months Ended
	Oct. 01, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
DESCRIPTION OF BUSINESS [Line Items]
Cash and cash equivalents		$ 35,847		$ 70,340
Accumulated deficit		370,704		345,892
Cash flows from operating activities		34,171	$ 27,639	$ 30,700
$37.5 Million Credit Facility \| Subsequent Event [Member]
DESCRIPTION OF BUSINESS [Line Items]
Amount drew down	$ 22,500
$37.5 Million Credit Facility \| Oxford Finance LLC
DESCRIPTION OF BUSINESS [Line Items]
Borrowings outstanding under credit facility		$ 37,500
Credit facility maturity date		Mar. 31, 2028

Fair Value Measurement and Fi_3

Fair Value Measurement and Financial Instruments - Schedule of Carrying Amounts and Fair Values of Financial Instruments (Details) - Money market funds - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Carrying Amount
Assets
Total assets	$ 27,163	$ 68,002
Fair Value
Assets
Total assets	27,163	68,002
Quoted Prices In Active Markets (Level 1)
Assets
Total assets	$ 27,163	$ 68,002

Accounts Receivable - Compositi

Accounts Receivable - Composition of Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Receivables [Abstract]
Gross accounts receivable - trade	$ 16,155	$ 15,239
Less: Allowances for doubtful accounts	(1,131)	(1,648)
Accounts receivable, net	$ 15,024	$ 13,591

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventory impairment charge	$ 1,900	$ 1,905

Property and Equipment and Ca_3

Property and Equipment and Capitalized Software - Summary of Composition of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 5,611	$ 5,048
Less: Accumulated depreciation	(3,545)	(3,057)
Property and equipment, net	2,066	1,991
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	666	462
Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	510	508
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,966	1,758
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	485	343
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,442	1,435
Rental Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	542	542
Property and equipment, net	$ 400	$ 500

Property and Equipment and Ca_4

Property and Equipment and Capitalized Software - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Depreciation and amortization expense	$ 0.5	$ 0.4	$ 1.5	$ 1
Prepaid expenses and other current assets
Property Plant And Equipment [Line Items]
Capitalized software cost, net	$ 3.9		$ 3.9		$ 3.6

Notes Receivables - Additional

Notes Receivables - Additional Information (Details) $ in Millions				3 Months Ended		9 Months Ended
	Mar. 31, 2023 USD ($) D	Jul. 14, 2022 USD ($)	Sep. 29, 2021 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Greenbrook TMS Inc \| Secured Promissory Note
Accounts, Notes, Loans and Financing Receivable [Line Items]
Term of notes receivable	4 years
Interest rate (as a percent)	7.65%
Percentage of unpaid amount	200%
Discount rate	20%
Number of day volume-weighted average closing price \| D	30
Principal amount of notes receivable	$ 6
Success TMS
Accounts, Notes, Loans and Financing Receivable [Line Items]
Repayment of notes issued		$ 10.5
Success TMS \| Secured Promissory Note
Accounts, Notes, Loans and Financing Receivable [Line Items]
Term of master sales agreement			5 years
Term of notes receivable			5 years
Principal amount of notes receivable			$ 10
Success TMS \| Secured Promissory Note \| Other income, net
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest income recognized				$ 0.2	$ 0.5	$ 0.4	$ 1

Notes Receivables net (Details)

Notes Receivables net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounts Notes, Loans And Financing, Receivable, Gross, Allowance, And Net [Abstract]
Current portion of notes receivables	$ 1,890	$ 230
Long-term notes receivable	4,299	362
Less: Allowances for credit losses	(148)
Notes receivable, net	$ 6,041	$ 592

Leases - Additional Information

Leases - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
Leases - Additional Information (Details) $ in Thousands	Sep. 30, 2023 USD ($) ft²	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) ft²	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Leases [Line Items]
Lessee, finance lease, lease not yet commenced, description			The Company does not currently have any finance leases or executed leases that have not yet commenced.
Operating lease, rent expense, net	$ 200	$ 200	$ 600	$ 600
Operating lease, weighted-average remaining lease term	4 years 3 months 18 days		4 years 3 months 18 days
Operating lease, weighted-average discount rate	7.20%		7.20%
Carrying amount of lease receivables	$ 1,700		$ 1,700
Unguaranteed residual assets	0		0
Operating lease income	20	70	100	200
Property and equipment, net	$ 2,066		$ 2,066		$ 1,991
NeuroStar Advanced Therapy Systems \| Minimum
Leases [Line Items]
Lessor sales-type lease, Term	3 years		3 years
NeuroStar Advanced Therapy Systems \| Maximum
Leases [Line Items]
Lessor sales-type lease, Term	4 years		4 years
Headquarters and Office Equipment, Including Copiers
Leases [Line Items]
Area of lease facility \| ft²	32,000		32,000
Rental Equipment
Leases [Line Items]
Property and equipment, net	$ 400		$ 400		$ 500
Rental equipment depreciation expense	$ 20	$ 20	$ 70	$ 70
Charlotte, North Carolina
Leases [Line Items]
Area of lease facility \| ft²	9,600		9,600

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information as Lessee Related to Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 807	$ 632

Leases - Schedule of Future Pay

Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Operating Lease Liabilities [Abstract]
Remainder of 2023	$ 215
2024	875
2025	898
2026	921
2027	882
2028	116
Total lease payments	3,907
Less imputed interest	(561)
Present value of operating lease liabilities	$ 3,346

Leases- Schedule of Profit Reco

Leases- Schedule of Profit Recognized on Sales-type Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Sales Type Lease Lease Income [Abstract]
Profit recognized at commencement, net	$ 13	$ 122	$ 60	$ 543
Total sales-type lease income	$ 13	$ 122	$ 60	$ 543

Leases - Schedule of Maturity A

Leases - Schedule of Maturity Analysis of Undiscounted Lease Receivables Related to Sales-type Leases (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Sales Type And Direct Financing Leases Lease Receivable Fiscal Year Maturity [Abstract]
Remainder of 2023	$ 298
2024	876
2025	390
2026	76
2027	28
Total sales-type lease receivables	$ 1,668

Prepaid Commission Expense - Ad

Prepaid Commission Expense - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Amortization Of Deferred Charges [Abstract]
Amortization period of deferred commissions			7 years
Amortization expense	$ 0.6	$ 0.5	$ 1.7	$ 1.3

Accrued Expenses- Summary of Co

Accrued Expenses- Summary of Composition of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payable And Accruals [Abstract]
Compensation and related benefits	$ 6,342	$ 11,201
Consulting and professional fees	713	761
Research and development expenses	278	678
Sales and marketing expenses	1,012	410
Warranty	198	328
Sales and other taxes payable	641	659
Other	853	800
Accrued expenses	$ 10,037	$ 14,837

Deferred Revenue - Summary of P

Deferred Revenue - Summary of Percentages of Deferred Revenue by Year (Details)	Sep. 30, 2023
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	100%
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]: 2023-10-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	29%
Revenue, remaining performance obligation, expected timing of satisfaction, period	3 months
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]: 2024-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	59%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]: 2025-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	11%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]: 2026-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	1%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Deferred Revenue - Additional I

Deferred Revenue - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($) customer	Sep. 30, 2022 USD ($) customer	Sep. 30, 2023 USD ($) customer	Sep. 30, 2022 USD ($) customer	Dec. 31, 2022 USD ($)
Disaggregation of Revenue [Line Items]
Revenue recognized	$ 400	$ 400	$ 1,700	$ 2,200
Number of customer accounted for more than 10% of revenues \| customer	1	1	1	1
Accounts receivable	$ 15,024		$ 15,024		$ 13,591
Credit concentration risk \| Customer 1
Disaggregation of Revenue [Line Items]
Accounts receivable	$ 2,100		$ 2,100		$ 5,200
Revenue \| Customer concentration risk \| Customer 1
Disaggregation of Revenue [Line Items]
Percentage of Revenues	15%	15%	17%	16%

Deferred Revenue - Summary of R

Deferred Revenue - Summary of Revenue Generated in Geographic Regions for Years Indicated (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Revenues	$ 17,884	$ 16,498	$ 51,034	$ 47,008
Revenue \| Geographic Concentration
Segment Reporting Information [Line Items]
Revenues	$ 17,884	$ 16,498	$ 51,034	$ 47,008
Percentage of Revenues	100%	100%	100%	100%
Revenue \| U.S. \| Geographic Concentration
Segment Reporting Information [Line Items]
Revenues	$ 17,211	$ 16,244	$ 49,464	$ 45,893
Percentage of Revenues	96%	98%	97%	98%
Revenue \| International \| Geographic Concentration
Segment Reporting Information [Line Items]
Revenues	$ 673	$ 254	$ 1,570	$ 1,115
Percentage of Revenues	4%	2%	3%	2%

Deferred Revenue - Summary of_2

Deferred Revenue - Summary of Revenue Generated in Product Category for Years Indicated (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Revenues	$ 17,884	$ 16,498	$ 51,034	$ 47,008
Product Category \| U.S. \| Revenue
Segment Reporting Information [Line Items]
Revenues	$ 17,211	$ 16,244	$ 49,464	$ 45,893
Percentage of Revenues	100%	100%	100%	100%
Product Category \| U.S. \| Revenue \| NeuroStar Advanced Therapy System
Segment Reporting Information [Line Items]
Revenues	$ 3,597	$ 3,934	$ 11,936	$ 11,959
Percentage of Revenues	21%	24%	24%	26%
Product Category \| U.S. \| Revenue \| Treatment Sessions
Segment Reporting Information [Line Items]
Revenues	$ 13,060	$ 11,864	$ 36,018	$ 32,627
Percentage of Revenues	76%	73%	73%	71%
Product Category \| U.S. \| Revenue \| Other
Segment Reporting Information [Line Items]
Revenues	$ 554	$ 446	$ 1,510	$ 1,307
Percentage of Revenues	3%	3%	3%	3%
Product Category \| International \| Revenue
Segment Reporting Information [Line Items]
Revenues	$ 673	$ 254	$ 1,570	$ 1,115
Percentage of Revenues	100%	100%	100%	100%
Product Category \| International \| Revenue \| NeuroStar Advanced Therapy System
Segment Reporting Information [Line Items]
Revenues	$ 258	$ 96	$ 573	$ 460
Percentage of Revenues	38%	38%	36%	41%
Product Category \| International \| Revenue \| Treatment Sessions
Segment Reporting Information [Line Items]
Revenues	$ 280	$ 31	$ 589	$ 214
Percentage of Revenues	42%	12%	38%	19%
Product Category \| International \| Revenue \| Other
Segment Reporting Information [Line Items]
Revenues	$ 135	$ 127	$ 408	$ 441
Percentage of Revenues	20%	50%	26%	40%

Debt - Summary of Composition o

Debt - Summary of Composition of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Outstanding principal	$ 37,500	$ 35,000
Accrued final payment fees	1,856	1,925
Less debt discounts	(2,505)	(971)
Total debt, net	36,851	35,954
Less current portion		(13,125)
Long-term debt, net	$ 36,851	$ 22,829

Debt- Additional Information (D

Debt- Additional Information (Details) $ in Millions		3 Months Ended		9 Months Ended
Debt- Additional Information (Details) $ in Millions	Mar. 29, 2023 USD ($) tranche	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Oct. 03, 2023 USD ($)	Sep. 29, 2023 USD ($)
Debt Instrument [Line Items]
Interest expense		$ 1.2	$ 1.1	$ 3.6	$ 3
Cash interest expense		1.1	0.9	3.1	2.5
Non-cash interest expense		$ 0.1	$ 0.2	$ 0.5	$ 0.5
Prepaid After First and on or Before Second Anniversary of Funding
Debt Instrument [Line Items]
Prepayment fees percentage	2%
Solar Capital Ltd
Debt Instrument [Line Items]
Prepayment fees percentage	2%
Trailing twelve month net product revenue first threshold limit to pay exit fee	$ 100
Trailing twelve month net product revenue Second threshold limit to pay exit fee	$ 125
Percentage of exit fee for liquidation, dissolution, winding up or change of control of the Company	4.95%
Percentage of exit fee upon achievement of any trailing twelve month revenues	1%
Percentage of exit fee upon achievement of both trailing twelve month revenues	2%
Capped exit fee percentage on term loan principal amount	2%
Solar Capital Ltd \| Prepaid on or Before First Anniversary of Funding
Debt Instrument [Line Items]
Prepayment fees percentage	3%
Solar Capital Ltd \| Prepaid After Second Anniversary of Funding
Debt Instrument [Line Items]
Prepayment fees percentage	1%
Solar Capital Ltd \| Term A Loan
Debt Instrument [Line Items]
Interest rate during the period	3.95%
Solar Capital Ltd \| Term A Loan \| Minimum
Debt Instrument [Line Items]
Interest rate during the period	5.65%
Solar Capital Ltd \| Term C Loan
Debt Instrument [Line Items]
Amount permitted to draw							$ 22.5
Solar Capital Ltd \| $35.0 Million Credit Facility
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 60
Term loans number of tranches \| tranche	3
Solar Capital Ltd \| $35.0 Million Credit Facility \| Term A Loan
Debt Instrument [Line Items]
Borrowings outstanding under credit facility	$ 35
Solar Capital Ltd \| $35.0 Million Credit Facility \| Term B Loan
Debt Instrument [Line Items]
Borrowings outstanding under credit facility	2.5
Solar Capital Ltd \| $35.0 Million Credit Facility \| Term C Loan
Debt Instrument [Line Items]
Borrowings outstanding under credit facility	22.5
Solar Capital Ltd \| $50.0 Million Credit Facility
Debt Instrument [Line Items]
Debt instrument final payment fee amount	1.2
Solar Capital Ltd \| Two Point Five Million Credits Facility [Member] \| Term B Loan
Debt Instrument [Line Items]
Borrowings outstanding under credit facility	$ 2.5
Solar Capital Ltd \| $22.5 Million Credit Facility \| Term C Loan \| Subsequent Event
Debt Instrument [Line Items]
Borrowings outstanding under credit facility						$ 22.5

Common Stock - Summary of Commo

Common Stock - Summary of Common Stock Issued and Reserved for Issuance (Details) - shares shares in Thousands	Sep. 30, 2023	Dec. 31, 2022
Stockholders Deficit [Line Items]
Shares of common stock issued	28,902	27,268
Shares of common stock reserved for issuance for:
Total shares of common stock issued and reserved for issuance	36,076	34,734
Common stock warrants
Shares of common stock reserved for issuance for:
Shares of common stock reserved for issuance	41	61
Stock Options Outstanding
Shares of common stock reserved for issuance for:
Shares of common stock reserved for issuance	1,271	1,301
Restricted stock units outstanding
Shares of common stock reserved for issuance for:
Shares of common stock reserved for issuance	3,634	3,901
Shares available for grant under stock incentive plans
Shares of common stock reserved for issuance for:
Shares of common stock reserved for issuance	893	1,140
Shares available for sale under employee stock purchase plan
Shares of common stock reserved for issuance for:
Shares of common stock reserved for issuance	1,335	1,063

Common Stock- Summary of Outsta

Common Stock- Summary of Outstanding Common Stock Warrants (Details) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	41	61
Exercise Price $9.73
Class Of Warrant Or Right [Line Items]
Warrants Outstanding		20
Exercise Price		$ 9.73
Expiration Date		2023-08
Exercise Price. $9.73
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	20	20
Exercise Price	$ 9.73	$ 9.73
Expiration Date	2024-03	2024-03
Exercise Price $9.73
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	21	21
Exercise Price	$ 9.73	$ 9.73
Expiration Date	2024-12	2024-12

Loss Per Share - Schedule of Po

Loss Per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Loss Per Share Calculation (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding excluded from diluted loss per share	1,271	1,424
Non-vested PRSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding excluded from diluted loss per share	395	395
Non-vested restricted stock units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding excluded from diluted loss per share	3,239	3,665
Common stock warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding excluded from diluted loss per share	41	75

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total	$ 1,855	$ 2,178	$ 5,693	$ 6,633
Cost of Revenues
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total	38	35	109	94
Sales and Marketing
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total	590	1,074	1,946	3,258
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total	1,052	939	3,134	2,950
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total	$ 175	$ 130	$ 504	$ 331

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) $ in Thousands, shares in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2022 shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) installment shares	Sep. 30, 2022 USD ($)	Dec. 31, 2020 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expenses		$ 1,855	$ 2,178	$ 5,693	$ 6,633
Stock options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expenses		100	200	300	500
Unrecognized compensation cost related to non-vested stock options		200		$ 200
Non-vested awards not yet recognized weighted-average period for recognition				9 months 18 days
Restricted Stock Units and PRSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expenses		1,800	$ 2,000	$ 5,300	$ 6,100
Non-vested awards not yet recognized weighted-average period for recognition				1 year 9 months 18 days
Unrecognized compensation cost related to non-vested restricted stock		$ 10,000		$ 10,000
Fair value of restricted stock vested				$ 8,300
2018 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Annual percentage increase in number of shares authorized for issuance				4%
Vesting terms of stock options				stock options vest 25% upon the first anniversary of the date of grant and the remainder ratably monthly thereafter for 36 months. Restricted stock units generally vest ratably in three equal installments on the first, second and third anniversaries of the grant date.
Number of vesting installments \| installment				3
Shares available for future issuance \| shares		0.6		0.6
2018 Plan \| PRSUs \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average price, number of days trailing				30 days
2018 Plan \| First Anniversary of Date of Grant
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage of stock options				25%
2018 Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for issuance \| shares		1.4		1.4
Maximum contractual term of stock options				10 years
2020 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of additional shares authorized for issuance \| shares	0.5
Shares available for future issuance \| shares		0.3		0.3
2020 Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for issuance \| shares						0.4

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Option Activity (Details) - Stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares under Option, Outstanding, Beginning balance	1,301
Number of Shares under Option, Forfeited	(30)
Number of Shares under Option, Outstanding, Ending balance	1,271
Number of Shares under Option, Exercisable	1,058
Number of Shares under Option, Vested and expected to vest	1,271
Weighted-average Exercise Price per Option, Outstanding, Beginning balance	$ 4.07
Weighted-average Exercise Price per Option, Forfeited	11.67
Weighted-average Exercise Price per Option, Outstanding, Ending balance	3.89
Weighted-average Exercise Price per Option, Exercisable	4.27
Weighted-average Exercise Price per Option, Vested and expected to vest	$ 3.89
Weighted-average Remaining Contractual Life, Outstanding	6 years 3 months 18 days
Weighted-average Remaining Contractual Life, Exercisable	6 years 3 months 18 days
Weighted-average Remaining Contractual Life, Vested and expected to vest	6 years 3 months 18 days
Aggregate average Intrinsic Value, Outstanding	$ 3
Aggregate average Intrinsic Value, Exercisable	3
Aggregate average Intrinsic Value, Vested and expected to vest	$ 3

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Restricted Stock Units and PRSUs Activity (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Restricted stock units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested, Beginning balance \| shares	3,506
Granted \| shares	1,640
Vested \| shares	(1,634)
Forfeited \| shares	(273)
Non-vested, Ending balance \| shares	3,239
Weighted-average Grant-date Fair Value, Non-vested, Beginning balance \| $ / shares	$ 4.29
Weighted-average Grant-date Fair Value, Granted \| $ / shares	4.73
Weighted-average Grant-date Fair Value, Vested \| $ / shares	4.38
Weighted-average Grant-date Fair Value, Forfeited \| $ / shares	5.08
Weighted-average Grant-date Fair Value, Non-vested, Ending balance \| $ / shares	$ 4.41
PRSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested, Beginning balance \| shares	395
Non-vested, Ending balance \| shares	395
Weighted-average Grant-date Fair Value, Non-vested, Beginning balance \| $ / shares	$ 6.77
Weighted-average Grant-date Fair Value, Non-vested, Ending balance \| $ / shares	$ 6.77

Segment Information - Additiona

Segment Information - Additional Information (Details)	9 Months Ended
Segment Information - Additional Information (Details)	Sep. 30, 2023 segment
Segments Geographical Areas [Abstract]
Number of operating business segment	1

Government Assistance (Details)

Government Assistance (Details) $ in Millions	9 Months Ended
Government Assistance (Details) $ in Millions	Sep. 30, 2023 USD ($)
Employee Retention Credit
Government Assistance [Line Items]
Government assistance amount recognized in income statement	$ 2.9